Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ · Healthcare
Rigel Pharmaceuticals, Inc. Operating Income 2016–2025
Rigel Pharmaceuticals, Inc. annual/quarterly operating income history and growth rate from 2016 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Rigel Pharmaceuticals, Inc. operating income for the quarter ending March 31, 2026 was 11.9 M, a 6.95% decrease year-over-year.
- Rigel Pharmaceuticals, Inc. operating income for the twelve months ending March 31, 2026 was 114.2 M, a 3616.83% increase year-over-year.
- Rigel Pharmaceuticals, Inc. annual operating income for 2025 was 125.5 M, a 418.63% increase from 2024.
- Rigel Pharmaceuticals, Inc. annual operating income for 2024 was 24.2 M, a 218.06% decrease from 2023.
- Rigel Pharmaceuticals, Inc. annual operating income for 2023 was -20.5 M, a 63.11% decrease from 2022.
- Rigel Pharmaceuticals, Inc. annual operating income for 2022 was -55.5 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Rigel Pharmaceuticals, Inc. Operating Income — FAQ
Rigel Pharmaceuticals, Inc. (RIGL) operating income over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
What is Rigel Pharmaceuticals, Inc.'s operating income?
Rigel Pharmaceuticals, Inc. (RIGL) reported operating income of $125M for fiscal 2025.
Where can I see RIGL's operating income history?
The chart and table above show Rigel Pharmaceuticals, Inc.'s operating income by year and by quarter, including the growth rate.